Prot #NU MS16H07: Phase II Multicenter Study of Natalizumab Plus Standard Steroid Treatment for High Risk Acute Graft-Versus-Host Disease

Project: Research project

Project Details

StatusFinished
Effective start/end date9/1/16 → 11/2/21

Funding

  • Icahn School of Medicine at Mount Sinai (Prot #NU MS16H07 // Prot #NU MS16H07)
  • Biogen Inc. (Prot #NU MS16H07 // Prot #NU MS16H07)